Towards evidence-based medicine for paediatricians: Question 2

Archives of Disease in Childhood: Education and Practice Edition

Volumn 93, Issue 4, 2008, Pages 131-132

  Banerjee, S ^a   Ayyash, H F ^b  

^a Queens House   (United Kingdom)

^b DONCASTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADOLESCENT; AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HOSTILITY; HUMAN; MALE; NOTE; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; TREATMENT OUTCOME; ARTICLE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; AGGRESSION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HOSTILITY; HUMANS; MALE; PROPYLAMINES;

EID: 49149096078     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2008.142356     Document Type: Note

References (13)

1. Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry 2007;61:713-19.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition. Washington, DC: American Psychiatric Association, 1994.
3. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on the attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004;14:11-28.
4. Guevara JP, Stein MT. Attention deficit hyperactivity disorder. In: Moyer VA, Elliott EJ, Davis RL, et al, eds. Evidence based pediatrics and child health. London: BMJ Books, 2000:341-50.
5. Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:525-40.
6. Faraone SV, Biederman J, Mick E, et al. A family study of psychiatric comorbidity in girls and boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2001;50:586-92.
7. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Technology appraisal 98. London: NICE, 2006.
8. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901.
9. Spencer T, Heiligenstein JH, Biederman J, et al. Results of 2 proof-of-concept, placebo controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7.
10. Eli Lilly and Company. Strattera [package insert]. Indianapolis: Eli Lilly and Company, 2007.
11. Garattini S, Bertele V. How can we regulate medicines better? BMJ 2007;335:803-5.
12. Bennett CL, Nebeker JR, Yarmold PR, et al. Evaluation of serious adverse drug reactions. Arch Intern Med 2007;167:1041-9.
13. Clarkson A, Ingleby E, Choonara I, et al. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child 2001;84:337-9.